Business Wire

RSA Recognized in 2024 Gartner® Magic Quadrant™ for Access Management

5.12.2024 13:00:00 CET | Business Wire | Press release

Share

RSA, the security-first identity leader, announced today that RSA® ID Plus, the world’s most secure identity and access management (IAM) platform has been named a Niche Player in the 2024 Gartner® Magic Quadrant™ for Access Management.

With only ten organizations named to the Gartner report, RSA believes that the Magic Quadrant signals the world’s top IAM vendors. ID Plus brings comprehensive identity protection to some of the world’s most security-sensitive organizations across banking, securities, insurance, and government. Available as SaaS, on-premises, or in hybrid configurations, ID Plus offers organizations flexibility in deployment and specialization in high-security workforce environments. Through various subscription models featuring a range of editions and add-ons, ID Plus meets diverse needs, supporting the evolving workforce requirements and regulatory landscapes throughout North America, South America, Europe, and the Asia-Pacific markets.

RSA believes that several capabilities and strengths contributed to ID Plus being listed in the 2024 Gartner Magic Quadrant for Access Management, including:

  • High customer satisfaction and retention
  • Specialization in workforce use cases, particularly for high-security verticals
  • Broad support for cloud, hybrid, and on-premises environments
  • A high-availability, high-security failover process that ensures uninterrupted access even during cloud outages
  • Integrations with existing data and applications that enable buyers to maintain local configurations

“For decades, RSA has set the standard in secure authentication, but our story goes far beyond that. Seeing ID Plus break into the 2024 Gartner Magic Quadrant for Access Management and being recognized as a workforce security specialist, we feel, highlights the work we’ve done to develop a unified identity platform capable of securing the entire identity lifecycle and protecting highly regulated industries,” said RSA CEO Rohit Ghai.

“We feel that being named to the Gartner Magic Quadrant establishes RSA as one of the world’s top ten IAM vendors, and we’re not planning on going anywhere,” said RSA Chief Product and Technology Officer Jim Taylor, who detailed why workforce access management challenges organizations, how RSA supports customer access management, and the organization's access management roadmap in a new blog post. “Workforce access management is hard because it demands balancing security, usability, and scalability without getting any component wrong. I’d rather RSA be known as a workforce security specialist than an access generalist: that’s always been where RSA delivers the most value and what our customers need. With hundreds of IAM vendors worldwide, this recognition validates our commitment to delivering the full range of access, authentication, governance, and lifecycle capabilities that every organization requires.”

“While we may be new to the Magic Quadrant, security-first industries have relied on our access management solutions for years,” said RSA President and Chief Business Officer Greg Nelson. “Security-first leaders in government, finance, energy, and other regulated industries have long trusted RSA to deliver robust identity security solutions. We believe this recognition from Gartner underscores the strength of our strategy and reinforces our commitment to lead across every component of identity.”

Recent enhancements to ID Plus—including expanded identity insights, Bring Your Own Identity (BYOI) options, and OAuth 2.0 capabilities supporting machine-to-machine and IoT access—will bring further workforce security depth to the solution. RSA will introduce mobile passkey functionality, advanced directory enhancements, and increased AI and machine learning capabilities to assist security administrators in mitigating evolving threats.

RSA will showcase these innovations at the Gartner Identity & Access Management Summit from December 9-11 in Grapevine, Texas. Attendees are invited to visit RSA at booth 633 to experience demonstrations of the latest passwordless authentication and identity governance and administration (IGA) advancements. Book your demo with RSA at the Gartner IAM Summit now.

Resources

Read Jim Taylor’s blog post
Book your demo with RSA at the Gartner Identity & Access Management Summit
Start your free, 45-day trial of RSA ID Plus today

About RSA

The AI-powered RSA Unified Identity Platform protects the world’s most secure organizations from today’s and tomorrow’s highest-risk cyberattacks. RSA provides the identity intelligence, authentication, access, governance, and lifecycle capabilities needed to prevent threats, secure access, and enable compliance. More than 9,000 security-first organizations trust RSA to manage more than 60 million identities across on-premises, hybrid, and multi-cloud environments. For additional information, visit our website to contact sales, find a partner, or learn more about RSA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241205057055/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye